DSpace Repository

Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression

Show simple item record

dc.contributor.author Cáceres, G.
dc.contributor.author Calderon, R.
dc.contributor.author Ugarte Gil, Cesar Augusto
dc.date.accessioned 2022-06-25T20:36:40Z
dc.date.available 2022-06-25T20:36:40Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/11841
dc.description.abstract Tuberculosis is one of the leading causes of death worldwide, primarily affecting low- and middle income countries and individuals with limited-resources within fractured health care systems. Unfortunately, the COVID-19 pandemic has only served to aggravate the already existing diagnostic gap, decreasing the number of people who get diagnosed and thereby complete successful treatment. In addition to this, comorbidities act as an external component that when added to the TB management equation, renders it even more complex. Among the various comorbidities that interact with TB disease, diabetes mellitus and depression are two of the most prevalent among non-communicable diseases within the TB population and merits a thoughtful consideration when the healthcare system provides care for them. TB patients with diabetes mellitus (TB-DM) or depression both have an increased risk of mortality, relapse and recurrence. Both of these diseases when in presence of TB present a ‘vicious-circle-like’ mechanism, meaning that the effect of each disease can negatively add up, in a synergistic manner, complicating the patient’s health state. Among TB-DM patients, high glucose blood levels can decrease the effectiveness of anti-tuberculosis drugs; however, higher doses of anti-tuberculous drugs could potentially decrease the effects of DM drugs. Among the TB-depression patients, not only do we have the adherence to treatment problems, but depression itself can biologically shift the immunological profile responsible for TB containment, and the other way around, TB itself can alter the hormonal balance of several neurotransmitters responsible for depression. In this paper, we review these and other important aspects such as the pharmacological interactions found in the treatment of TB-DM and TB-depression patients and the implication on TB care and pharmacological considerations. en_US
dc.language.iso eng
dc.publisher SAGE Publications
dc.relation.ispartofseries Therapeutic Advances in Infectious Disease
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject depression en_US
dc.subject therapy en_US
dc.subject diabetes en_US
dc.subject tuberculosis en_US
dc.subject comorbidities en_US
dc.title Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1177/20499361221095831
dc.relation.issn 2049-9361


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics